The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.

@article{Bogaert1995TheER,
  title={The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.},
  author={Walter van den Bogaert and Els Van Der Schueren and Jean Claude Horiot and M De Vilhena and Simon Schraub and Vera Svoboda and Giorgio Arcangeli and M A De Pauw and M van Glabbeke},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={1995},
  volume={35 2},
  pages={100-6}
}
In trial no. 22811 on a randomized comparison of multiple fractions per day (MFD), with or without misonidazole, to conventional fractionation in advanced head and neck cancer, a large number (523) of patients was entered in a short period of time. No differences in treatment results were obtained, but the study created an important database, allowing for detailed evaluation of the most important factors influencing prognosis. In univariate analysis, factors significantly influencing survival… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…